Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Yada KanjanapanDaphne DayLisa WangHamad Al-SawaiheyEngy AbbasAmirali NaminiLillian L SiuAaron HansenAlbiruni Abdul RazakAnna SpreaficoNatasha LeighlAnthony M JoshuaMarcus O ButlerDavid HoggMary Anne ChappellLudmilla SoultaniKayla ChowSamantha BoujosPhilippe L BedardPublished in: Cancer (2019)
HPD was observed in 7% of patients with solid tumors treated with immunotherapy. HPD was not associated with CSAEs, age, tumor type, or the type of immunotherapy but was more common in females.
Keyphrases